Tirzepatide reset the weight-loss benchmark in 2022. Three years later the comparative-effectiveness data has caught up, and the answer to "is tirzepatide better than semaglutide for obesity?" is now anchored in head-to-head trial evidence rather than indirect comparisons. The clinical implications are concrete; the prescribing implications are less so.
The two compounds in one paragraph
Both are once-weekly subcutaneous incretin-mimetic peptides. Semaglutide is a GLP-1 receptor mono-agonist (FDA-approved as Wegovy for chronic weight management at the 2.4 mg dose). Tirzepatide is a dual GIP/GLP-1 receptor co-agonist (FDA-approved as Zepbound at doses up to 15 mg). The shared mechanism is incretin pathway activation — slowed gastric emptying, post-prandial insulin support, central appetite suppression. The mechanistic divergence is GIP receptor engagement, which preclinical work suggests amplifies GLP-1 effects on energy balance and glucose handling.
SURMOUNT-5: the head-to-head that ended the indirect-comparison era
The SURMOUNT-5 trial reported in 2025 ([Aronne et al., NEJM — PMID 40353578]) randomized adults with obesity to maximum-tolerated tirzepatide versus maximum-tolerated semaglutide 2.4 mg over 72 weeks. Tirzepatide produced statistically greater weight reduction at every prespecified timepoint. The primary endpoint demonstrated approximately 20% body weight loss on tirzepatide compared with approximately 14% on semaglutide. The trial was powered to detect superiority, not non-inferiority, and the result was unambiguous.
Earlier evidence converged on the same direction
SURMOUNT-1 ([Jastreboff et al., NEJM — PMID 35658024]) had previously established tirzepatide's place-in-therapy at 22.5% body weight reduction at the 15 mg dose over 72 weeks in patients without diabetes. STEP-1 ([Wilding et al., NEJM — PMID 33567185]) had set the semaglutide benchmark at 14.9% body weight reduction over 68 weeks. Indirect comparisons of these endpoints had suggested tirzepatide's edge for several years; SURMOUNT-5 confirmed the gap held in a single randomized population.
What the head-to-head doesn't settle
SURMOUNT-5 is one trial in one population. It does not establish:
- Cardiovascular outcomes superiority. Semaglutide has reported cardiovascular benefit in obesity without diabetes ([Lincoff et al., NEJM SELECT — PMID 37952131]). Tirzepatide's CV outcomes data is still maturing.
- Renal outcomes. Semaglutide's FLOW trial ([Perkovic et al., NEJM — PMID 38785209]) demonstrated kidney-disease progression benefit in type 2 diabetes with chronic kidney disease.
- Side-effect tolerability differentials at matched-effect doses. The trial reported broadly similar gastrointestinal adverse-event profiles, but real-world tolerability remains a clinical judgment call.
- Cost-effectiveness or access. List prices and payer coverage are not equivalent across the two compounds.
Where this leaves the GLP-1 versus dual-agonist conversation
The era of debating "is tirzepatide more effective than semaglutide for body weight" is over. Tirzepatide is more effective at maximum-tolerated dose for weight loss. The remaining clinical conversation is which secondary endpoints matter for the individual patient — cardiovascular protection, renal protection, glycemic effect, tolerability profile, and access constraints — and which compound the comparator-trial evidence supports for that endpoint.
For research investigators, SURMOUNT-5 is the pivotal head-to-head reference for any future obesity-pharmacology trial design. Indirect-comparison meta-analyses on this question are now superseded by direct evidence.
Practical context for this site's readers
The compounds discussed here are FDA-approved prescription medications. They are clinically prescribed in the GLP3 Weight Loss program by board-certified physicians following standard-of-care evaluation. Research-grade peptide reference compounds for laboratory investigation are available separately through the Telos catalog and are not substitutes for prescribed therapy.